[1]陈婷,李小平,高强国,等.不同方法检测急性移植物抗宿主病患者的血清标志物[J].第三军医大学学报,2019,41(23):2280-2284.
 CHEN Ting,LI Xiaoping,GAO Qiangguo,et al.Different methods for detecting serum markers in patients with acute graft versus host disease[J].J Third Mil Med Univ,2019,41(23):2280-2284.
点击复制

不同方法检测急性移植物抗宿主病患者的血清标志物(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
41卷
期数:
2019年第23期
页码:
2280-2284
栏目:
专题报道
出版日期:
2019-12-15

文章信息/Info

Title:
Different methods for detecting serum markers in patients with acute graft versus host disease
作者:
陈婷李小平高强国高蕾刘耀张诚孔佩艳高力冯一梅饶军张曦
400037 重庆,陆军军医大学(第三军医大学)第二附属医院血液病医学中心,全军血液病中心,创伤、烧伤与复合伤研究国家重点实验室1;400038 重庆,陆军军医大学(第三军医大学)基础医学院细胞生物学教研室2
Author(s):
CHEN Ting1 LI Xiaoping1 GAO Qiangguo2 GAO Lei1 LIU Yao1 ZHANG Cheng1 KONG Peiyan1 GAO Li1 FENG Yimei1 RAO Jun1 ZHANG Xi1

1State Key Laboratory of Trauma, Burns and Combined Injury, Medical Center of Hematology, PLA Center for Hematology, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037; 2Department of Cell Biology, College of Basic Medical Sciences, Army Medical University (Third Military Medical University), Chongqing, 400038, China

关键词:
异基因造血干细胞移植急性移植物抗宿主病血清生物标志物IL-7IL-27CD127
Keywords:
allogeneic hematopoietic stem cell transplantation acute graft versus host disease serum biomarkers IL-7 IL-27 CD127
分类号:
R392.4; R446.6; R617
文献标志码:
A
摘要:

目的采用两种方法检测急性移植物抗宿主病(acute graft versus host disease,aGVHD)患者的血清生物标志物,筛选出有临床价值的生物标志物,并阐明两种方法检查结果的一致性,建立aGVHD的生物标志物筛查流程。方法收集2016年4月至2018年4月本血液病医学中心进行异基因造血干细胞移植的患者60例,采用蛋白质芯片法和ELISA检测同时期接受异基因造血干细胞移植后发生(aGVHD组,n=30)和未发生急性移植物抗宿主病患者(对照组,n=30)的血清细胞因子表达水平。结果两种不同实验方法检测均发现,aGVHD组患者血清中IL-7、IL-27表达水平高于对照组(P<0.05),而CD127在aGVHD组患者中表达水平降低(P<0.05)。其中IL-27表达水平与急性移植物抗宿主病的疾病严重程度相关(P<0.05)。两种检测方法的ROC曲线下面积均在0.7~0.9之间,差异无统计学意义。结论蛋白质芯片和ELISA两种检测方法的准确度高,结果一致。可以建立先通过蛋白质芯片法筛选出有临床意义的重点细胞因子,再扩大样本量后通过ELISA法进行重复验证的血清生物标志物筛查流程,利于临床开展。

Abstract:

ObjectiveTo clarify the consistency of the results of the 2 methods for detecting serum biomarkers in patients with acute graft versus host disease (aGVHD) in order to screen out biomarkers with clinical value and to establish a biomarker screening process for aGVHD. MethodsSixty patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in our medical center from April 2016 to April 2018 were recruited in this study. Protein chip and ELISA were used to detect the serum cytokine levels in the patients with aGVHD (n=30) and those without (control group, n=30). ResultsBoth detection methods showed that the serum levels of IL-7 and IL-27p were significantly higher (P<0.05), while the expression level of CD127 was decreased (P<0.05) in the aGVHD group than the control. The expression level of IL-27 was correlated with the severity of aGVHD (P<0.05). The area under the receiver operating characteristic (ROC) curve was between 0.7 and 0.9, with no significant differences between the 2 methods. ConclusionBoth protein chip and ELISA have high accuracy and consistency in the detection of serum biomarkers in aGVHD patients. It is possible to establish a high-throughput screening of clinically significant cytokines by protein chip, and then expanding the sample size and repeating the validation by ELISA, which is conducive to clinical development.

参考文献/References:

[1]SHOUVAL R, BONIFAZI F, FEIN J, et al. Validation of the acute leukemia-EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi-center GITMO cohort[J]. Am J Hematol, 2017, 92(5): 429-434. DOI:10.1002/ajh.24677.
[2]BRGGEN M C, PETZELBAUER P, GREINIX H, et al. Epidermal elafin expression is an indicator of poor prognosis in cutaneous graft-versus-host disease[J]. J Invest Dermatol, 2015, 135(4): 999-1006. DOI:10.1038/jid.2014.489.
[3]PACZESNY S, BRAUN T M, LEVINE J E, et al. Elafin is a biomarker of graft-versus-host disease of the skin[J]. Sci Transl Med, 2010, 2(13): 13ra2. DOI:10.1126/scitranslmed.3000406.
[4]PACZESNY S. Biomarkers for posttransplantation outcomes[J]. Blood, 2018, 131(20): 2193-2204. DOI:10.1182/blood-2018-02-791509.
[5]HE F C, HOLTAN S G. Biomarkers in graft-versus-host disease: from prediction and diagnosis to insights into complex graft/host interactions[J]. Curr Hematol Malig Rep, 2018, 13(1): 44-52. DOI:10.1007/s11899-018-0433-2.
[6]GUPTA V, BALL S E, SAGE D, et al. Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning[J]. Bone Marrow Transplant, 2005, 35(5): 467-471. DOI:10.1038/sj.bmt.1704799.
[7]ANTIN J H, FERRARA J L. Cytokine dysregulation and acute graft-versus-host disease[J]. Blood, 1992, 80(12): 2964-2968.
[8]FERRARA J L, LEVINE J E, REDDY P, et al. Graft-versus-host disease[J]. Lancet, 2009, 373(9674): 1550-1561. DOI:10.1016/s0140-6736(09)60237-3.
[9]ZEISER R, BLAZAR B R. Acute graft-versus-host disease-biologic process, prevention, and therapy[J]. N Engl J Med, 2017, 377(22): 2167-2179. DOI:10.1056/NEJMra1609337.
[10]HIANT S, SHAMIM Z, PETER L, et al. Impact of donor IL-7Rɑ polymorphism on recipient plasma IL-7 levels and acute GVHD following allogeneic stem cell transplantation[C]. Orlando: ASH 52nd Annual Meeting,2010.
[11]HAN F, HU R, SU M, et al. A human recombinant IL-7/HGFβ hybrid cytokine enhances antitumor immunity in mice[J]. Am J Cancer Res, 2017, 7(8): 1714-1723.
[12]SCHIFFER L, KMPERS P, DAVALOS-MISSLITZ A M, et al. B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE)[J]. Nephrol Dial Transplant, 2009, 24(12): 3708-3712. DOI:10.1093/ndt/gfp343.
[13]WOJNO E D, HUNTER C A. New directions in the basic and translational biology of interleukin-27[J]. Trends Immunol, 2012, 33(2): 91-97. DOI:10.1016/j.it.2011.11.003.
[14]PFLANZ S, TIMANS J C, CHEUNG J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells[J]. Immunity, 2002, 16(6): 779-790. DOI:10.1016/s1074-7613(02)00324-2.
[15]TAKEDA A, HAMANO S, YAMANAKA A, et al. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment[J]. J Immunol, 2003, 170(10): 4886-4890. DOI:10.4049/jimmunol.170.10.4886.
[16]MARILLIER R G, UYTTENHOVE C, GORIELY S, et al. IL-27p28 is essential for parent-to-F1 acute graft-versus-host disease[J]. Eur J Immunol, 2014, 44(7): 2064-2073. DOI:10.1002/eji.201444491.

更新日期/Last Update: 2019-12-09